Open AccessLosartan no tratamento das lesões musculares
Author(s) -
Filipe Cabral,
Pedro C. Barata
Publication year - 2021
Language(s) - English
DOI - 10.23911/losartan_musculo_2021_mar
Subject(s) - losartan , medicine , fibrosis , regeneration (biology) , blocking (statistics) , pharmacology , receptor , computer science , angiotensin ii , biology , microbiology and biotechnology , computer network
Muscle injuries are very common in sports medicine. Frequently the muscle repair process ends in the formation of a fibrotic scar, that not only limits the complete functional recovery, but also increases the likelihood of injury recurrence. TGF-β1 is the main profibrogenic factor involved in this healing process. By blocking its activity, Losartan has proven it efficacy in reducing fibrosis and increasing regenerative and functional capacity post muscle injury. Therefore, its use should be considered as an alternative therapeutic for this kind of injuries.